Hematologic malignancies/pediatric malignancies
Usui, N.
Gan to Kagaku Ryoho. Cancer and ChemoTherapy 36(5): 742-743
2009
ISSN/ISBN: 0385-0684 PMID: 19496282 Document Number: 631576
Document emailed within 1 workday
Related Documents
Usui, N. 2019: Hematologic Malignancies/Pediatric Malignancies Current Guidelines of Clinical Management and Drug Therapy for Hematological Malignancies Gan to Kagaku Ryoho. Cancer and ChemoTherapy 46(5): 859-861Murakami, H.; Saitoh, T.; Kasamatsu, T. 2016: Hematologic Malignancies/Pediatric Malignancies. III. Treatment of Relapsed/Refractory Multiple Myeloma Gan to Kagaku Ryoho. Cancer and ChemoTherapy 43(5): 539-544
Usui, N. 2017: Hematologic Malignancies/Pediatric Malignancies Acute Leukemia - Current Treatment and Future Perspective Gan to Kagaku Ryoho. Cancer and ChemoTherapy 44(5): 378-379
Usui, N. 2011: Hematologic malignancies/ pediatric malignancies-chronic myeloid leukemia Gan to Kagaku Ryoho. Cancer and ChemoTherapy 38(5): 744
Wierda, W.G.; Kipps, T.J. 2000: Gene therapy of hematologic malignancies Seminars in Oncology 27(5): 502-511
Nara, N. 2002: Molecular diagnosis in hematologic malignancies Rinsho Byori. Japanese Journal of Clinical Pathology 50(4): 331-336
Baltz, J.K.; Montello, M.J. 1993: Cladribine for the treatment of hematologic malignancies Clinical Pharmacy 12(11): 805
Gutterman, J.U. 1988: The role of interferons in the treatment of hematologic malignancies Seminars in Hematology 25(3 Suppl 3: 3-8
San-Miguel, J.F.; Bartram, C.; Campana, D.; Andreeff, M. 1994: Minimal residual disease in hematologic malignancies Revista de Investigacion Clinica; Organo del Hospital de Enfermedades de la Nutricion Suppl: 147-152
Ueoka, H.; Ueno, K.; Yamane, T.; Toyoda, K.; Endo, H.; Nishihara, R.; Takahashi, I.; Ohnoshi, T.; Kitajima, K.; Kimura, I. 1983: Phase Ii study of mitoxantrone for hematologic malignancies Gan to Kagaku Ryoho. Cancer and ChemoTherapy 10(11): 2399-2402
Garewal, H.; Durie, B.G. 1981: Beta 2-microglobulin: a potentially useful marker for hematologic malignancies Arizona Medicine 38(12): 912-913
deMagalhaes-Silverman, M.; Bloom, E.J.; Donnenberg, A.; Lister, J.; Pincus, S.; Rybka, W.B.; Ball, E.D. 1996: Toxicity of busulfan and cyclophosphamide (BU/CY2) in patients with hematologic malignancies Bone Marrow Transplantation 17(3): 329-333
Curtis, M.A. 2003: New monoclonal antibodies for hematologic malignancies (and breast cancer) Medicine and Health Rhode Island 86(8): 256-257
Hernández, J.A.; Martino, R.; Pericas, R.; Sureda, A.; Brunet, S.; Domingo-Albós, A. 1998: Achromobacter xylosoxidans bacteremia in patients with hematologic malignancies Haematologica 83(3): 284-285
Keating, M.J.; O'Brien, S.; Plunkett, W.; Robertson, L.E.; Gandhi, V.; Estey, E.; Dimopoulos, M.; Cabanillas, F.; Kemena, A.; Kantarjian, H. 1994: Fludarabine phosphate: a new active agent in hematologic malignancies Seminars in Hematology 31(1): 28-39
Giles, F.J. 2002: The emerging role of angiogenesis inhibitors in hematologic malignancies Oncology 16(5 Suppl 4: 23-29
Nagura, E.; Kawashima, K. 1986: Secondary malignancies associated with hematological malignancies following anticancer treatment Gan to Kagaku Ryoho. Cancer and ChemoTherapy 13(4 Part 2): 1464-1474
Champlin, R. 1991: Immunobiology of bone marrow transplantation as treatment for hematologic malignancies Transplantation Proceedings 23(4): 2123-2127
Nenova, I.S.; Goranov, S.E.; Mateva, N.G.; Ananoshtev, N.H. 2003: Treatment with fluorated quinolones of febrile neutropenia in patients with hematologic malignancies Folia Medica 45(1): 13-19
Lorgeot, V.; Praloran, V.; Turlure, P.; Denizot, Y. 1997: Concentrations of serum leukemia inhibitory factor (LIF) in patients with hematologic malignancies Leukemia 11(2): 311-312